Chinese drugmaker Thousand Oaks Biopharmaceuticals, Inc. has collected $45 million in Series A financing.

Led by New Alliance Capital, the round also had participation from ADDOR Capital, Tenyall & Sumin, Broadhi Capital and Bluebay Capital.

With the capital raised, Thousand Oaks will enhance its phase II contract development and manufacturing organization.

Thousand Oaks will also extend its integrated chemistry, manufacturing and controls services and ramp up its media production capacity.